Everything below concerns LY3437943. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-17. Numbers and descriptions here follow the published literature rather than marketing material.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatographic profiles reveal related impurities, truncated sequences, and oxidation products, while mass measurement confirms the expected molecular mass. Purity values for research material are typically reported as a percentage by peak area. Reference standards help calibrate retention behavior across instruments. Independent laboratories emphasize method suitability because results depend heavily on column chemistry, gradient, and detection wavelength. Batch-to-batch comparison relies on the same validated method.
Investigational peptide material is commonly distributed as a lyophilized powder in sealed vials. The solid form appears as a white to off-white cake or powder and is hygroscopic once opened. Peptides of this size are sensitive to moisture, repeated freeze-thaw cycles, and prolonged exposure to ambient light. Handling practices therefore emphasize desiccation, minimal vial opening, and cold storage. Working aliquots are often prepared to avoid repeatedly warming the bulk container.
== TCI Foundation == TCI Foundation, the social responsibility arm of Transport Corporation of India. The foundation is involved in initiatives related to health, education, women’s development, disability, and disaster relief.
=== February === February 9, 2011 Latvia Latvia leaves deep recession with an annualised growth of 3.7% in the last quarter of 2010, meaning the Latvian economy only shrank by 0.2% in 2010, compared to 18% in 2009.
=== Management of acute flare === During moderate or severe symptomatic attacks, a short course (usually 3–5 days) of high doses of corticosteriods is the usual approach. Initially, oral corticosteroids are used; if that is ineffective, an intravenous course can be tried. Milder attacks may not need treatment. Although targeted at acute attacks, they might also have a small longer-term benefit. Severe attacks that do not respond to corticosteroids might be treatable by plasma exchange.
== Units == The dalton (symbol: Da) is the standard unit that is used for indicating mass on an atomic or molecular scale (atomic mass). The unified atomic mass unit (symbol: u) is equivalent to the dalton. One dalton is one-twelfth of the mass of one atom of carbon-12, and is 1.66053906892(52)×10−27 kg. The amu without the "unified" prefix is an obsolete unit based on oxygen, which was replaced in 1961.
Teasel; fruit is an aggregation of cypselas. Tuliptree; fruit is an aggregation of samaras. Magnolia and peony; fruit is an aggregation of follicles. American sweet gum; fruit is an aggregation of capsules. Sycamore; fruit is an aggregation of achenes. The pistils of the raspberry are called drupelets because each pistil is like a small drupe attached to the receptacle. In some bramble fruits, such as blackberry, the receptacle, an accessory part, elongates and then develops as part of the fruit, making the blackberry an aggregate-accessory fruit. The strawberry is an aggregate-accessory fruit, with its seeds in achenes.
Sources: en.wikipedia.org
=== Parasocial contact hypothesis === The parasocial contact hypothesis posits that positive portrayals of minority groups in media help to reduce stigmas and stereotypes surrounding these groups. Applying this theory to the portrayal of mental illnesses, if media represents well-rounded, accurate characters who are experiencing mental illness, it can challenge the long-standing stereotypes and work to reduce the stigma surrounding mental health. Furthermore, when in-groups and out-groups engage in positive contact, there is the possibility of challenging stereotypes and prejudice.
The white shark is the sole living species in the genus Carcharodon and is one of five living species of the family Lamnidae. The other four members of this family are the mako sharks, porbeagle, and salmon shark. The family belongs to the Lamniformes, the order of mackerel sharks. The white shark first appears in the fossil record in the Pacific basin around 6–5 mya, between the late Miocene and early Pliocene. Like all sharks, the white shark's skeleton is made primarily of soft cartilage that does not preserve well. As a result, the overwhelming majority of fossils are teeth. Nevertheless, paleontologists have traced the emergence of the white shark and its immediate ancestry to a large extinct shark known as Carcharodon hastalis. This species had teeth similar to the modern white shark's, except for the cutting edges, which lacked serrations. C. hastalis occupied a similar position in the food web to modern white sharks and was probably mostly fish-eating, with some marine mammals in its diet, though its lack of serrations made it a less efficient predator of them. Around 8–6 mya, a Pacific population of C. hastalis evolved into C. hubbelli. This divergent lineage was characterized by a gradual development of serrations over the next few million years. Teeth from the same time period may exhibit significant variation in shape and their serrations, which may be indicative of persistent interbreeding with C. hastalis for at least some time. White sharks descended from C.
Considering all decay modes, various models indicate a shift of the center of the island (i.e., the longest-living nuclide) from 298Fl to a lower atomic number, and competition between alpha decay and spontaneous fission in these nuclides; these include 100-year half-lives for 291Cn and 293Cn, a 1000-year half-life for 296Cn, a 300-year half-life for 294Ds, and a 3500-year half-life for 293Ds, with 294Ds and 296Cn exactly at the N = 184 shell closure. It has also been posited that this region of enhanced stability for elements with 112 ≤ Z ≤ 118 may instead be a consequence of nuclear deformation, and that the true center of the island of stability for spherical superheavy nuclei lies around 306Ubb (Z = 122, N = 184). This model defines the island of stability as the region with the greatest resistance to fission rather than the longest total half-lives; the nuclide 306Ubb is still predicted to have a short half-life with respect to alpha decay. The island of stability for spherical nuclei may also be a "coral reef" (i.e., a broad region of increased stability without a clear "peak") around N = 184 and 114 ≤ Z ≤ 120, with half-lives rapidly decreasing at higher atomic number, due to combined effects from proton and neutron shell closures. Another potentially significant decay mode for the heaviest superheavy elements was proposed to be cluster decay by Romanian physicists Dorin N. Poenaru and Radu A. Gherghescu and German physicist Walter Greiner.
From the mesoderm surrounding the neural tube and notochord, the skull, vertebral column, and the membranes of the brain and medulla spinalis are developed. Because it originates from the primitive node and is ultimately positioned with the mesodermal space, it is considered to be derived from mesoderm. A postembryonic vestige of the notochord is found in the nucleus pulposus of the intervertebral discs. Isolated notochordal remnants may escape their lineage-specific destination in the nucleus pulposus and instead attach to the outer surfaces of the vertebral bodies, from which notochordal cells largely regress.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.